NCT07197242Not yet recruiting
Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization
Assessment of Lipoprotein(a) in Patients Undergoing Elective Percutaneous Coronary Revascularization: Implications for Cardiovascular Risk Stratification
Source: ClinicalTrials.gov · Last updated 29 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study investigates the role of Lipoprotein(a) \[Lp(a)\] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 156 (estimated)
- First submitted
- 20 Sept 2025
- Start date
- 1 Oct 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Assiut University
- Diseases
- Coronary artery disease
- NCT number
- NCT07197242
What you commit to
- Study type: Observational
- Planned participants: 156
- From 1 Oct 2026 to the primary completion date, 30 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute coronary syndrome within 30 days
- Cardiogenic shock
- Prior heart transplant or left ventricular assist device (LVAD)
- Life expectancy less than 1 year due to non-cardiac causes
- Participation in a blinded Lp(a)-lowering outcome trial at the time of enrollment
Who the study is looking for
- Adults aged 18 years or older
- Undergoing elective PCI for stable coronary artery disease
- Ability to provide informed consent
- Willingness to undergo blood sampling prior to PCI
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.